Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals)

Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals) $ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2019 CAD ($)	Mar. 31, 2018 CAD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)
Statement Line Items [Line Items]
Total Marketable securities	$ 11,892	$ 26
Term deposit, one [Member]
Statement Line Items [Line Items]
Total Marketable securities		$ 26		$ 20
Term deposit, one [Member] \| Bottom of range [member]
Statement Line Items [Line Items]
Financial instrument, interest rate		2.23%
Term deposit, one [Member] \| Top of range [member]
Statement Line Items [Line Items]
Financial instrument, maturity date		March 13, 2019
Term deposit, two[Member]
Statement Line Items [Line Items]
Total Marketable securities	$ 2,696		$ 2,020
Financial instrument, interest rate	2.50%
Term deposit, two[Member] \| Bottom of range [member]
Statement Line Items [Line Items]
Financial instrument, maturity date	April 8, 2019
Term deposit, two[Member] \| Top of range [member]
Statement Line Items [Line Items]
Financial instrument, maturity date	March 12, 2020
Treasury bills [Member]
Statement Line Items [Line Items]
Total Marketable securities	$ 9,196
Treasury bills [Member] \| Bottom of range [member]
Statement Line Items [Line Items]
Financial instrument, interest rate	1.83%
Financial instrument, maturity date	April 2, 2019
Treasury bills [Member] \| Top of range [member]
Statement Line Items [Line Items]
Financial instrument, interest rate	1.90%
Financial instrument, maturity date	July 25, 2019